We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Nirmal Kaur

Nirmal Kaur MD

Director, Inflammatory Bowel Disease Center, Henry Ford Health System, Novi, Michigan

Dr. Kaur is the Director of the Inflammatory Bowel Disease Center at Henry Ford Health System in Detroit, Michigan.  She serves as Principal Investigator on several clinical trials related to IBD, and has implemented a system for adherence to AGA quality measures for all IBD patients at Henry Ford.  Dr. Kaur completed her residency and fellowship training at the University of Michigan in 2010.

Disclosures

Present: Consultant, Takeda Pharmaceuticals; Research funding, Janssen Pharmaceuticals, Genentech-Roche Pharmaceuticals, AbbVie Pharmaceuticals

Past:  Consultant, AbbVie Pharmaceuticals; AMAG Pharmaceuticals; UCB Pharmaceuticals

Recent Contributions to PracticeUpdate:

  1. Liver Enzyme Elevated With Biological Therapy for IBD